GAG
CYCN icon

Goodman Advisory Group’s Cyclerion Therapeutics CYCN Stock Holding History

Goodman Advisory Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18
Closed – – 164
2022
Q4 		$0 Hold
18
– – ﹤0.01% 147
2022
Q3 		$0 Buy
+18
New +$309 ﹤0.01% 162

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goodman Advisory Group's CYCN Position: Q1 2023 in Review

Goodman Advisory Group sold out of Cyclerion Therapeutics (CYCN) in Q1 2023, closing a stake of 18 shares.

Goodman Advisory Group first reported a position in CYCN in Q3 2022 and held it in 2 quarters. The position peaked at $0 in Q4 2022. 34 funds tracked by Wall St. Rank hold CYCN as of Q1 2023.

  • Goodman Advisory Group reported no remaining Cyclerion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Goodman Advisory Group sold 18 Cyclerion Therapeutics shares in Q1 2023.
  • Goodman Advisory Group first reported a position in Cyclerion Therapeutics in Q3 2022 and held it in 2 quarters.
  • Goodman Advisory Group's Cyclerion Therapeutics position peaked at $0 in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2023.

Based on Goodman Advisory Group's 13F filing for Q1 2023, filed 15 May 2023.